Coherus BioSciences announced that sales of CIMERLI to retinal specialists have exceeded 100,000 doses since commercial launch on October 3, 2022. CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis for all approved indications. In August 2023, CIMERLI achieved 25% market share of the ranibizumab market*, making it the #1 ranibizumab biosimilar. Coherus plans to report CIMERLI net sales for the third quarter when the company reports Q3 2023 financial results in November.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CHRS:
- Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
- CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
- Coherus Biosciences announces support for Rare Cancer Day
- Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Coherus Biosciences receives FDA CRL for UDENYCA ONBODY BLA